All In Biotech

Drug Trial Radar · NCT01456585

Phase 1 Study of Preoperative Gemcitabine Plus CP-870, 893 Followed by Addition of CP-870,893 to Standard -Of-care Adjuvant Chemoradiation for Patients With Newly Diagnosed Resectable Pancreatic Carcinoma

Phase 1 Study of Preoperative Gemcitabine Plus CP-870,893 Followed by Addition of CP-870,893 to Standard -Of-care Adjuvant Chemoradiation for Patient With Newly Diagnosed Resectable Pancreatic Carcinoma

Last checked: Nov 19, 2026Latest source record: Aug 27, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

10

Planned (sponsor's estimate)

Start

Apr 2012

Primary completion

Apr 2013

Study completion Apr 2013

Sponsor

Lead sponsor
Abramson Cancer Center at Penn MedicineAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 21, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a pilot study to evaluate the role of the addition of CP870, 893 to the neoadjuvant and adjuvant setting for patients with resectable pancreatic cancer. Patients will receive standard surgery followed by chemoradiation for their disease, but one dose of gem/cp 870,893 will be pre-op and 3 doses post-op.

Conditions

  • Adenocarcinoma Pancreas

Interventions

  • GemcitabineOther

  • CP-870,893Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with adverse events

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Abramson Cancer Center of the University of Pennsylvania

    Philadelphia, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.